Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisS

How an imprint can lead to cancer

David Secko
CMAJ May 10, 2005 172 (10) 1286; DOI: https://doi.org/10.1503/cmaj.050423
David Secko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Mutations in DNA may not be the sole mechanism that leads to cancer. New research suggests that variations in the imprint left on a genome by a parent can influence tumour development. The mechanism, which appears to be linked to how cells differentiate, takes us another step closer to understanding the factors that predispose some people to cancer.

Figure

Figure. Photo by: Corbis Canada

Epigenetics and cancer

Parental imprinting is an area in the field of epigenetics. Whereas genetics is concerned with DNA, epigenetics is the study of chemical modifications of the DNA–protein complexes that form chromosomes (i.e., chromatin). In the dominant modern view, the etiology of cancer centres on genetic changes, usually in the form of mutations to oncogenes or tumour suppressor genes, that result in unchecked cellular growth. Lately, however, it is becoming clear that epigenetic changes also play a role.1

The effect of methyl groups on DNA is one example: adding methyl groups turns tumour suppressor genes off, whereas removal of methyl groups activates normally silent oncogenes. Genomic imprinting is another: imprinting occurs when both maternal and paternal alleles are present, but 1 allele is preferentially expressed. This parentally based difference is thought to be involved in viability, growth and behaviour. Abnormal imprinting is thought to contribute, for example, to the development of Beckwith – Wiedemann syndrome (BWS).1,2 This disorder results in a predisposition to tumour growth early in life, often manifested as Wilms' tumours. Although BWS is associated with genetic changes, it has also been linked to the loss of imprinting of IGF2, the human insulin-like growth factor II gene.2 This gene is normally expressed from the paternal chromosome only, with the maternal copy “silent” owing to imprinting. This imprint loss, and the increases in IGF2 protein levels that follow, contribute to the pathogenesis of BWS, likely because of the protein's role as a growth factor.

Increases in IGF2 protein concentrations are also found in various human cancers (e.g., colorectal cancer), which raises the question of whether epigenetic mechanisms generally influence our risk of cancer.

Although BWS is rare, work in Feinberg's laboratory3,4 suggests that loss of imprinting may be a more general phenomenon.3 In 2003, loss of imprinting of the IGF2 gene was detected in normal lymphocytes and the colonic mucosa of 10% of healthy adults.3 The risk of colorectal adenomas among those with loss of imprinting was 3.5– 5 times that of healthy adult subjects with normal imprinting.5

In their latest work,4 Feinberg's team confirmed that association in an experiment in which female mice that would pass on either an imprinted or a nonimprinted copy of IGF2 were crossed with male mice possessing a mutation (Apc) in the adenomatous polyposis coli gene that predisposes mice (and humans) to familial colonic polyposis. Although the offspring of these parents were all predisposed to cancer, only half were affected by a loss of imprinting of IGF2. The mice with abnormal imprinting acquired twice as many intestinal adenomas as those whose imprinting was normal. The intestinal crypts (spaces between villi) in abnormally imprinted mice were found to be longer, and also associated with increased numbers of undifferentiated epithelial cells. In addition, Feinberg's group4 found that some human patients who have a loss of imprinting also appear to have more undifferentiated cells in their colons, which suggests that the cells may be precancerous.

These observations suggest that mutations in parental imprinting can influence cell differentiation and may as a consequence increase cancer risk. Such links provide a first peek at one of the mechanisms by which epigenetics may contribute to cancer development. The work also raises questions: Does abnormal imprinting of genes unrelated to cancer create environments that predispose people to disease?4 Is epithelial differentiation linked to the development of cancer? Future study should bring more about imprinting to light.

References

  1. 1.↵
    Feinberg AP, Tycko B. The history of cancer epigenetics [review]. Nat Rev Cancer 2004;4:143-53.
    OpenUrlPubMed
  2. 2.↵
    Walter J, Paulsen M. Imprinting and disease [review]. Semin Cell Dev Biol 2003;14:101-10.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299(5613):1753-5.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Sakatani T, Kaneda A, Iacobuzio-Donahue C, Carter MG, de Boom Witzel S, Okano H, et al. Loss of imprinting of IGF2 alters intestinal maturation and tumorigenesis in mice. Science 2005;307(5717):1976-8.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Klein G. Surveillance team against cancer. Nature 2005;434(7030):150.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (10)
CMAJ
Vol. 172, Issue 10
10 May 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How an imprint can lead to cancer
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How an imprint can lead to cancer
David Secko
CMAJ May 2005, 172 (10) 1286; DOI: 10.1503/cmaj.050423

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
How an imprint can lead to cancer
David Secko
CMAJ May 2005, 172 (10) 1286; DOI: 10.1503/cmaj.050423
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Epigenetics and cancer
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Cancer & oncology
    • Genetics
    • Molecular medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire